BIOMARKER:

KRAS G12R

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

›

KRAS G12R	Colon Cancer	KRAS G12R	Colon Cancer	cetuximab Resistant: B - Late Trials cetuximab Resistant : B	cetuximab Resistant: B - Late Trials cetuximab Resistant : B
KRAS G12R	Colorectal Cancer	KRAS G12R	Colorectal Cancer	panitumumab Resistant: B - Late Trials panitumumab Resistant : B	panitumumab Resistant: B - Late Trials panitumumab Resistant : B
KRAS G12R	Pancreatic Adenocarcinoma	KRAS G12R	Pancreatic Adenocarcinoma	selumetinib Sensitive: C3 – Early Trials selumetinib Sensitive : C3	selumetinib Sensitive: C3 – Early Trials selumetinib Sensitive : C3
KRAS G12R	Pancreatic Cancer	KRAS G12R	Pancreatic Cancer	cobimetinib Sensitive: C3 – Early Trials cobimetinib Sensitive : C3	cobimetinib Sensitive: C3 – Early Trials cobimetinib Sensitive : C3
KRAS G12R	Hepatocellular Cancer	KRAS G12R	Hepatocellular Cancer	sorafenib + BAY86-9766 Sensitive: C3 – Early Trials sorafenib + BAY86-9766 Sensitive : C3	sorafenib + BAY86-9766 Sensitive: C3 – Early Trials sorafenib + BAY86-9766 Sensitive : C3
KRAS G12R	Non Small Cell Lung Cancer	KRAS G12R	Non Small Cell Lung Cancer	erlotinib Resistant: C3 – Early Trials erlotinib Resistant : C3	erlotinib Resistant: C3 – Early Trials erlotinib Resistant : C3
KRAS G12R	Gastric Cancer	KRAS G12R	Gastric Cancer	imatinib Resistant: C4 – Case Studies imatinib Resistant : C4	imatinib Resistant: C4 – Case Studies imatinib Resistant : C4
KRAS G12R	Colorectal Cancer	KRAS G12R	Colorectal Cancer	sunitinib Resistant: D – Preclinical sunitinib Resistant : D	sunitinib Resistant: D – Preclinical sunitinib Resistant : D
KRAS G12R	Thyroid Gland Carcinoma	KRAS G12R	Thyroid Gland Carcinoma	trametinib + dasatinib Sensitive: D – Preclinical trametinib + dasatinib Sensitive : D	trametinib + dasatinib Sensitive: D – Preclinical trametinib + dasatinib Sensitive : D
KRAS G12R	Thyroid Gland Carcinoma	KRAS G12R	Thyroid Gland Carcinoma	trametinib Sensitive: D – Preclinical trametinib Sensitive : D	trametinib Sensitive: D – Preclinical trametinib Sensitive : D
KRAS G12R	Thyroid Gland Carcinoma	KRAS G12R	Thyroid Gland Carcinoma	dasatinib + SCH772984 Sensitive: D – Preclinical dasatinib + SCH772984 Sensitive : D	dasatinib + SCH772984 Sensitive: D – Preclinical dasatinib + SCH772984 Sensitive : D
KRAS G12R	Thyroid Gland Medullary Carcinoma	KRAS G12R	Thyroid Gland Medullary Carcinoma	RTB101 + RAF265 Sensitive: D – Preclinical RTB101 + RAF265 Sensitive : D	RTB101 + RAF265 Sensitive: D – Preclinical RTB101 + RAF265 Sensitive : D
KRAS G12R	Thyroid Gland Carcinoma	KRAS G12R	Thyroid Gland Carcinoma	dasatinib + selumetinib Sensitive: D – Preclinical dasatinib + selumetinib Sensitive : D	dasatinib + selumetinib Sensitive: D – Preclinical dasatinib + selumetinib Sensitive : D
KRAS G12R	Thyroid Gland Carcinoma	KRAS G12R	Thyroid Gland Carcinoma	dasatinib Sensitive: D – Preclinical dasatinib Sensitive : D	dasatinib Sensitive: D – Preclinical dasatinib Sensitive : D
KRAS G12R	Thyroid Gland Anaplastic Carcinoma	KRAS G12R	Thyroid Gland Anaplastic Carcinoma	GSKJ4 Sensitive: D – Preclinical GSKJ4 Sensitive : D	GSKJ4 Sensitive: D – Preclinical GSKJ4 Sensitive : D